posted by AHIP
on April 10, 2019
On April 10, 2019, AHIP submitted a statement for the official record of a House Energy and Commerce Committee hearing that focused on the high cost of insulin.
Our statement emphasizes that AHIP’s members are strongly committed to ensuring that patients with diabetes can get affordable insulin to help control their blood glucose levels. We explain that health insurance providers have a strong history of advancing innovative approaches to help their enrollees successfully manage and control diabetes, prevent complications, and improve their quality of life.
We also highlight data showing that the price of insulin—just like the price of countless other prescription drugs—has increased sharply over the past decade, just as the prevalence of diabetes is on the rise. We caution that while insulin products have been on the market for almost a century, there is limited competition from lower cost generics primarily due to aggressive efforts by brand name drug manufacturers to block generic drug entry.
Our statement highlights the “CREATES Act” (H.R. 965) as a legislative solution that would help reduce barriers to the entry of lower cost generic drugs into the marketplace. We further emphasize that AHIP’s members support market-based solutions that hold drug makers accountable for high list prices and put downward pressure on prescription drug prices through competition, consumer choice, and open and honest drug pricing.